Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.46 |
| ▸ | MPL | P40238 | 5/20 | 0.40 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.40 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.40 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | TEK | Q02763 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 5/20 | 0.40 |
| ▸ | BCR | P11274 | 5/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243665 | 0.95 | PIP4K2C (0.49) | PIP4K2CMPLPIP4K2APIP4K2BPIKFYVE | |
| Trifluoroacetic Acid SCHEMBL1244312 | 0.90 | PIP4K2C (0.45) | PIP4K2CMPLPIP4K2APIP4K2BPIKFYVE | |
| SCHEMBL1244613 | 0.89 | PIP4K2C (0.51) | PIP4K2CPIP4K2APIP4K2BPIKFYVEKDR | |
| Trifluoroacetic Acid SCHEMBL1243616 | 0.88 | PIP4K2C (0.45) | PIP4K2CMPLPIP4K2APIP4K2BPIKFYVE | |
| Trifluoroacetic Acid SCHEMBL1242002 | 0.88 | PIP4K2C (0.43) | PIP4K2CMPLPIP4K2APIP4K2BPIKFYVE | |
| Trifluoroacetic Acid SCHEMBL1244552 | 0.88 | PTGS1 (0.43) | PIP4K2CPIP4K2APIP4K2BPIKFYVEKDR | |
| Trifluoroacetic Acid SCHEMBL1243959 | 0.87 | PIP4K2C (0.44) | PIP4K2CMPLPIP4K2APIP4K2BPIKFYVE | |
| SCHEMBL1243893 | 0.87 | PIP4K2C (0.51) | PIP4K2CPIP4K2APIP4K2BPIKFYVEEGFR | |
| Benzamide SCHEMBL28526510 | 0.87 | PIP4K2C (0.46) | PIP4K2CPIP4K2APIP4K2BPIKFYVEKDR | |
| SCHEMBL1243675 | 0.87 | PIP4K2C (0.47) | PIP4K2CMPLPIP4K2APIP4K2BPIKFYVE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879853-B2 | tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer | BAYER SCHERING PHARMA AG (DE) | 2011-02-01 | — | — | US | disclosed |
| EP-1763526-B1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2009-06-24 | — | — | EP | disclosed |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | ATLANTA PHARMA AG (DE) | 2007-09-06 | — | — | US | disclosed |
| EP-1763526-A1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Altana Pharma AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006000589-A1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | CDK2, DCK, DTYMK | PIP4K2C 52/4885MPL 777/4885PIP4K2A 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.